Correlation of heart rate response to dipyridamole stress during SPECT myocardial perfusion imaging with clinical factors

Document Type : Original Article

Authors

1 Student Research Committee, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Nuclear Medicine, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

Abstract

Introduction: Myocardial perfusion imaging (MPI) with pharmacologic stress is a useful technique for evaluation of suspected coronary artery disease (CAD). Heart rate responses (HRR) to vasodilators such as dipyridamole mirror autonomic activity and may provide important prognostic information in CAD patients. In this study, the impact of baseline characteristics of patients including age and gender on the expected HRR has been assessed.
Methods: This retrospective study included database of 2584 patients (1575 female, 1009 male) who were referred to the nuclear medicine department for pharmacologic MPI. The HRR to dipyridamole was calculated as ratio of maximal heart rate (HR) during or shortly after dipyridamole infusion to baseline HR. The association of HRR with age, gender, presence of other known CAD risk factors and perfusion findings was evaluated.
Results: Significant correlation was found between HRR and sex, age, diabetes mellitus (DM), hypertension (HTN), and chronic kidney disease (CKD) (P < 0.001) in both univariate and multivariate analysis. The mean HRR was also significantly higher in patients with normal perfusion on SPECT MPI as compared to patients with abnormal findings, however, multivariate regression analysis showed no significant correlation. In the subgroup of patients with no CAD risk factors, HRR was significantly higher in women under age 55 years.
Conclusion: The HRR during dipyridamole infusion depends on age and gender, irrespective of presence of other CAD risk factors and should be considered in the interpretation of. Besides, DM, HTN and CKD are also correlated with lower HRR to dipyridamole stress.

Keywords

Main Subjects

References

  1. Hatazawa J, Sabih D, Li Y, Pradhan PK, Paez D. Nuclear Cardiology in Asia. Semin Nucl Med. 2020 May;50(3):270-9. 
  2. Henzlova MJ, Duvall WL, Einstein AJ, Travin MI, Verberne HJ. ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers. J Nucl Cardiol. 2016 Jun;23(3):606-39. 
  3. Ghaedian T, Kalhor L, Sadra H, Hossein Tehrani M. The role of myocardial perfusion SPECT in short-term cardiac prognosis of end-stage renal disease. Iranian Journal of Nuclear Medicine. 2022;30(1):47-56.
  4. Tajik Rostami M, Mirshahvalad SA, Familrashtian S, Ghanbari H, Dehghani S. Assessing the role of supine and prone positioning on left ventricular volumes, ejection fraction, and heart rate using ECG-gated [99mTc]Tc-MIBI myocardial perfusion scan. Iran J Nucl Med. 2023;31(2):151-156.
  5. Leppo JA. Dipyridamole myocardial perfusion imaging. J Nucl Med. 1994 Apr;35(4):730-3.
  6. Hellsten Y, Nyberg M, Jensen LG, Mortensen SP. Vasodilator interactions in skeletal muscle blood flow regulation. J Physiol. 2012 Dec 15;590(24):6297-305.
  7. Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B, Wang W, Iskandrian AE. Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J. 2009 Apr;157(4):771-6.
  8. AlJaroudi W, Campagnoli T, Fughhi I, Wassouf M, Ali A, Doukky R. Prognostic value of heart rate response during regadenoson stress myocardial perfusion imaging in patients with end stage renal disease. J Nucl Cardiol. 2016 Jun;23(3):560-9.
  9. Bravo PE, Hage FG, Woodham RM, Heo J, Iskandrian AE. Heart rate response to adenosine in patients with diabetes mellitus and normal myocardial perfusion imaging. Am J Cardiol. 2008 Oct 15;102(8):1103-6.
  10. Hage FG, Dean P, Iqbal F, Heo J, Iskandrian AE. A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. J Nucl Cardiol. 2011 Dec;18(6):1086-94. 
  11. Gebhard C, Messerli M, Lohmann C, Treyer V, Bengs S, Benz DC, Giannopoulos AA, Kudura K, von Felten E, Schwyzer M, Gaemperli O, Gräni C, Pazhenkottil AP, Buechel RR, Kaufmann PA. Sex and age differences in the association of heart rate responses to adenosine and myocardial ischemia in patients undergoing myocardial perfusion imaging. J Nucl Cardiol. 2020 Feb;27(1):159-170.
  12. Hage FG, Perry G, Heo J, Iskandrian AE. Blunting of the heart rate response to adenosine and regadenoson in relation to hyperglycemia and the metabolic syndrome. Am J Cardiol. 2010 Mar 15;105(6):839-43.
  13. Abidov A, Hachamovitch R, Hayes SW, Ng CK, Cohen I, Friedman JD, Germano G, Berman DS. Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion study. Circulation. 2003 Jun 17;107(23):2894-9.
  14. Johnston DL, Hodge DO, Hopfenspirger MR, Gibbons RJ. Clinical determinants of hemodynamic and symptomatic responses in 2,000 patients during adenosine scintigraphy. Mayo Clin Proc. 1998 Apr;73(4):314-20.
  15. Clarke B, Conradson TB, Dixon CM, Barnes PJ. Reproducibility of heart rate changes following adenosine infusion in man. Eur J Clin Pharmacol. 1988;35(3):309-11.
  16. Homma S, Gilliland Y, Guiney TE, Strauss HW, Boucher CA. Safety of intravenous dipyridamole for stress testing with thallium imaging. Am J Cardiol. 1987 Jan 1;59(1):152-4.
  17. Rongen GA, Brooks SC, Pollard MJ, Ando S, Dajani HR, Notarius CF, Floras JS. Effect of adenosine on heart rate variability in humans. Clin Sci (Lond). 1999 Jun;96(6):597-604.
  18. Conradson TB, Clarke B, Dixon CM, Dalton RN, Barnes PJ. Effects of adenosine on autonomic control of heart rate in man. Acta Physiol Scand. 1987 Dec;131(4):525-31.
  19. Aksut SV, Pancholy S, Cassel D, Cave V, Heo J, Iskandrian AS. Results of adenosine single photon emission computed tomography thallium-201 imaging in hemodynamic nonresponders. Am Heart J. 1995 Jul;130(1):67-70.
  20. Ogilby JD, Iskandrian AS, Untereker WJ, Heo J, Nguyen TN, Mercuro J. Effect of intravenous adenosine infusion on myocardial perfusion and function. Hemodynamic/angiographic and scintigraphic study. Circulation. 1992 Sep;86(3):887-95
  21. Vaccarino V, Wilmot K, Al Mheid I, Ramadan R, Pimple P, Shah AJ, Garcia EV, Nye J, Ward L, Hammadah M, Kutner M, Long Q, Bremner JD, Esteves F, Raggi P, Quyyumi AA. Sex differences in mental stress-induced myocardial ischemia in patients with coronary heart disease. J Am Heart Assoc. 2016 Aug 24;5(9):e003630.
  22. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet. 1998 Feb 14;351(9101):478-84.
  23. Gupta A, Wang Y, Spertus JA, Geda M, Lorenze N, Nkonde-Price C, D'Onofrio G, Lichtman JH, Krumholz HM. Trends in acute myocardial infarction in young patients and differences by sex and race, 2001 to 2010. J Am Coll Cardiol. 2014 Jul 29;64(4):337-45.
  24. Izadnegahdar M, Singer J, Lee MK, Gao M, Thompson CR, Kopec J, Humphries KH. Do younger women fare worse? Sex differences in acute myocardial infarction hospitalization and early mortality rates over ten years. J Womens Health (Larchmt). 2014 Jan;23(1):10-7.
  25. Lehto HR, Lehto S, Havulinna AS, Ketonen M, Lehtonen A, Kesäniemi YA, Airaksinen KJ, Salomaa V. Sex differences in short- and long-term case-fatality of myocardial infarction. Eur J Epidemiol. 2011 Nov;26(11):851-61.
  26. Nabel EG. Heart disease prevention in young women: sounding an alarm. Circulation. 2015 Sep 15;132(11):989-91.
  27. Vaccarino V, Badimon L, Corti R, de Wit C, Dorobantu M, Manfrini O, Koller A, Pries A, Cenko E, Bugiardini R. Presentation, management, and outcomes of ischaemic heart disease in women. Nat Rev Cardiol. 2013 Sep;10(9):508-18.
  28. Lee KH, Yoon JK, Lee MG, Lee SH, Lee WR, Kim BT. Dipyridamole myocardial SPECT with low heart rate response indicates cardiac autonomic dysfunction in patients with diabetes. J Nucl Cardiol. 2001 Mar-Apr;8(2):129-35.
  29. Gerritsen J, Dekker JM, TenVoorde BJ, Kostense PJ, Heine RJ, Bouter LM, Heethaar RM, Stehouwer CD. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: the Hoorn Study. Diabetes Care. 2001 Oct;24(10):1793-8.
  30. Maser RE, Mitchell BD, Vinik AI, Freeman R. The association between cardiovascular autonomic neuropathy and mortality in individuals with diabetes: a meta-analysis. Diabetes Care. 2003 Jun;26(6):1895-901.
  31. O'Brien IA, McFadden JP, Corrall RJ. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med. 1991 Jun;79(290):495-502.
  32. Valensi P, Sachs RN, Harfouche B, Lormeau B, Paries J, Cosson E, Paycha F, Leutenegger M, Attali JR. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care. 2001 Feb;24(2):339-43. 
  33. De Lorenzo A, Lima RS. Influence of chronic renal failure on the heart rate response to dipyridamole in patients undergoing myocardial perfusion SPECT. J Nucl Cardiol. 2008 Mar-Apr;15(2):193-200.

Files

Share

How to cite

Statistics